drugset
drugset / Trial / NCT06336096

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

NCT06336096 ↗

Phase 1 Completed 48 enrolled Vertex Pharmaceuticals Incorporated
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK) of suzetrigine (SUZ; VX-548) and its metabolite along with its safety and tolerability, in healthy participants.

Timeline

Start
2024-03-28
Primary completion
2024-06-19
Completion
2024-06-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Suzetrigine Small molecule — Oral

Indications

No indication recorded.